Biotech Values

[JohnWayne]

BMY:

“One minor correction to your post, OS secondary endpoints for nivolumab + ipilimumab vs chemo is in TMB>=10 mutations/Mb population, only nivolumab vs chemo is in PD-L1+ and TMB>=13 mutations/Mb population.”

Yes that’s a secondary endpoint, but the Part 1 has two co-primary endpoints for O+Y: PFS in TMB-H (which was at AACR), and OS in PD-L1+ (which is still immature). Check NEJM if you want more details. This means that they could be in situation where they show primary endpoint PFS in one biomarker group (TMB-H) but OS in another biomarker group (PD-L1+). Extremely bizarre. Best case for BMY is all these OS primary and secondary endpoints are positive, but not sure how realistic that is...